Robaxin
(Methocarbamol)ApprovedSmall molecule
Robaxin is one of 28 small molecule programs targeting Ventral Hernia. It is currently in Approved.
3
Indications
9
Total Trials
3
Active Trials
27
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
18 competitors in Rib Fracture
#DrugCompanyPhaseTrials
1Journavx
Vertex PharmaceuticalsApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Advil
KKenvue Brands
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Tylenol
KKenvue Brands
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Ketalar
AAultman Health Foundation
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Trial1 trial
Rib Fracture1 trial
Total Knee Replacement1 trial
4 more indications
Kidney Calculi1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
ROBAXIN
NDA NDA011790
Jan 1, 1982
ROBAXIN
NDA NDA011011
Jul 30, 2025
ATMEKSI
NDA NDA219843
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Methocarbamol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]